Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Randomized, Placebo-controlled, Double-blind, Parallel-group Study of KWA-0711 Administered Orally for 4 Weeks to Evaluate Its Efficacy and Safety, and to Determine Its Optimal Dose in Patients With Chronic Constipation (CC)

NCT02281630 is registered in ClinicalTrials.gov with Kissei Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT02281630
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02281630 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Randomized, Placebo-controlled, Double-blind, Parallel-group Study of KWA-0711 Administered Orally for 4 Weeks to Evaluate Its Efficacy and Safety, and to Determine Its Optimal Dose in Patients With Chronic Constipation (CC)
Lead sponsor
Kissei Pharmaceutical Co., Ltd.
Phase
Phase 2
Overall status
Completed
Start date
October 15, 2014
Completion date
Not reported
Enrollment
388 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic constipation